Benralizumab for previously treated severe nasal polyps [ID1659]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Cochlear implants for children and adults with severe to profound deafness (TA566)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 7 March 2019
Continuous positive airway pressure for the treatment of obstructive sleep apnoea/hypopnoea syndrome (TA139)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 20 August 2021Published: 26 March 2008
Dupilumab for treating chronic rhinosinusitis with nasal polyps (terminated appraisal) (TA648)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 9 September 2020
Mepolizumab for treating severe chronic rhinosinusitis with nasal polyps (terminated appraisal) (TA847)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 29 November 2022
Omalizumab for treating chronic rhinosinusitis with nasal polyps (terminated appraisal) (TA678)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 February 2021
Sirolimus for treating angiofibroma from tuberous sclerosis complex in people 6 years and older [ID3990]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 18 September 2024
SQ HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (review of TA834) [ID6280]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 9 July 2024
SQ HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (terminated appraisal) (TA834)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 12 October 2022
STG320 for treating allergic rhinitis or rhinoconjunctivitis caused by house dust mites [ID1278]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Tezepelumab for treating severe chronic rhinosinusitis with nasal polyps TS ID 11918Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Topical rapamycin for treating facial angiofibromas associated with tuberous sclerosis complex in people 6 years and over TS ID 11936Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC